Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 991.76M | 990.26M | 862.80M | 696.63M | 715.37M | 523.08M |
Gross Profit | 103.53M | 102.85M | 118.64M | 149.85M | 80.36M | 61.56M |
EBITDA | 13.31M | 32.95M | 31.71M | 113.59M | 86.44M | 44.42M |
Net Income | 4.27M | 8.17M | 7.19M | 66.03M | 40.24M | 10.46M |
Balance Sheet | ||||||
Total Assets | 0.00 | 1.10B | 799.56M | 789.07M | 816.24M | 861.23M |
Cash, Cash Equivalents and Short-Term Investments | 11.43M | 18.43M | 15.78M | 124.24M | 11.62M | 3.13M |
Total Debt | 0.00 | 123.18M | 126.09M | 147.36M | 208.11M | 178.50M |
Total Liabilities | -677.63M | 449.29M | 371.16M | 383.76M | 552.70M | 637.05M |
Stockholders Equity | 677.63M | 649.16M | 428.39M | 405.31M | 263.54M | 224.19M |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -197.36M | 2.71M | 7.83M | 4.54M | 18.85M |
Operating Cash Flow | 0.00 | -194.31M | 3.82M | 10.80M | 13.19M | 20.11M |
Investing Cash Flow | 0.00 | -2.92M | 12.03M | 2.82M | -8.47M | -1.10M |
Financing Cash Flow | 0.00 | 199.88M | 3.23M | -17.32M | 4.17M | -18.12M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | ₹2.48B | 30.08 | ― | 2.36% | 2924.94% | ||
60 Neutral | ₹1.78B | 49.80 | ― | -4.74% | -41.53% | ||
55 Neutral | ₹1.41B | 20.16 | 1.32% | -14.16% | -6.46% | ||
54 Neutral | ₹1.31B | 309.48 | ― | 15.13% | -4518.87% | ||
52 Neutral | ₹708.72M | 25.03 | ― | -31.82% | 340.75% | ||
51 Neutral | $7.86B | -0.33 | -41.57% | 2.23% | 23.26% | -2.03% | |
39 Underperform | ₹1.52B | ― | ― | -31.91% | -38.46% |
Vaishali Pharma Ltd. has announced an amendment to its Memorandum of Association (MOA) following a Special Resolution passed via postal ballot. The amendment involves the inclusion of new business activities to ensure the company’s growth and expansion, allowing it to conduct business in various sectors such as nutraceuticals, surgical items, and financial activities. This strategic move is expected to enhance the company’s operational scope and market positioning.
Vaishali Pharma Ltd. has announced changes in its management structure following a postal ballot where shareholders approved the appointment of Mr. Bhaveshkumar Popatlal Upadhyay as a Non-Executive Independent Director and the re-appointment of Mr. Manish Bhagwandas Ved as an Independent Director for another five-year term. These appointments are expected to strengthen the company’s leadership team, leveraging Mr. Upadhyay’s extensive experience in business and HR management within the pharmaceutical industry, potentially enhancing the company’s strategic positioning and operational effectiveness.